ATS 2024 Final Program

Click on the session title to view the speakers

121

MONDAY • MAY 20

10:11 Severe Asthma Phenotypes in the Pediatric Population: More Than Just Eosinophils, IgE, and FeNO 10:28 What Is Disease Remission and Is it Achievable for Children with Severe Asthma?

CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM

B8 SEVERE CHILDHOOD ASTHMA: NEW PERSPECTIVES ON PHENOTYPES, MANAGEMENT, AND DISEASE REMISSION Assemblies on Pediatrics; Allergy, Immunology and Inflammation 9:15 a.m. - 10:45 a.m. Marriott Marquis San Diego Marina Grand Ballroom 8-9 (Lobby Level, North Tower) Target Audience This session will appeal to pediatric pulmonologists, pediatric allergists, fellows in training, advanced health care providers, and nurses who care for children with severe asthma, as well as scientists conducting research in this field. Objectives At the conclusion of this session, the participant will be able to: • learn new evidence on how to phenotype and select the best biologic and non-biologic therapy for children with severe asthma • discuss how low lung function should be monitored and managed in children with severe asthma • review the definition of disease remission and if remission is possible in children with severe asthma Children with severe asthma account for up to 50% of pediatric asthma costs. In this scientific symposium, a panel of experts in the field will review emerging evidence on the pathogenesis, evaluation, and phenotyping of severe asthma in the pediatric population. In addition, they will discuss recent studies on biologic and non-biologic therapies approved for the management of severe asthma in children and how these therapies could modify the natural history of the disease, potentially leading to its remission. 9:15 Patient Speaker 9:20 Management of Children with Severe Asthma Before Starting a Biologic 9:37 Breaking Down the Current Evidence on How to Select a Biologic for the Management of Severe Childhood Asthma 9:54 Low Lung Function in Severe Childhood Asthma: Determinants, Progression, and Management

CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM

B9 50 YEARS OF DYSANAPSIS: WHAT WE HAVE LEARNED AND WHERE WE ARE GOING Assemblies on Respiratory Structure and Function; Environmental, Occupational and Population Health; Pediatrics 9:15 a.m. - 10:45 a.m.

San Diego Convention Center Room 29A-D (Upper Level)

Target Audience Clinical and research trainees and providers Objectives

At the conclusion of this session, the participant will be able to: • understand the concept of dysanapsis and its contribution to chronic obstructive lung disease risk • describe the early-life origins of dysanapsis and the potential opportunities to promote resilient lung development for lifelong lung health • appreciate the advantages and limitations of current methods to assess dysanapsis and the need to develop better techniques The term “dysanapsis” was introduced in 1974 to describe a hypothesis that disproportionate airway tree growth may be relevant to obstructive lung physiology and disease risk. Over the past 50 years, this prescient hypothesis has been confirmed using state-of-the art measures and its clinical relevance across the lifespan has been demonstrated in multiple large cohorts. Attendees of this scientific symposium will gain a historical and contemporary understanding of the genetic and environmental origins of dysanapsis and its expanding relevance to lung health in the 21st century. 9:15 The Past 50 Years: A Brief History of Dysanapsis 9:30 Dysanapsis in Early Life: Origins, Trajectories and Clinical Relevance

ATS 2024 Conference Program • San Diego, CA